Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Inclusion criteria

• Participants at least 20 years but under 65 years of age;
• Participants of American Society of Anesthesiologists (ASA) class 1-3;
• Participants scheduled for a surgical procedure under general anesthesia requiring neuromuscular relaxation with the use of a neuromuscular blocking agent (NMBA) with an anticipated duration of surgery between 2 and 5 hours;
• Participants scheduled for a surgical procedure in supine position;
• Participants who had given written informed consent.

Exclusion criteria

• Participants in whom difficult intubation was expected because of anatomical malformations;
• Participants known or suspected to have neuromuscular disorders affecting NMB and/or significant renal dysfunction. In Germany, this also included serum creatinine and blood urea nitrogen outside local reference ranges;
• Participants known or suspected to have a (family) history of malignant hyperthermia;
• Participants known or suspected to have an allergy to medications used during general anesthesia;
• Participants receiving medication interfering with NMBAs, such as antibiotics, anticonvulsants and Mg^2+; based on the dose and time of administration;
• Pregnant or lactating females;
• Female participants of childbearing potential not using any birth control or using only hormonal contraception as birth control;
• Participants who had already participated in trial CT 19.4.312, or in another trial with sugammadex;
• Participants who had participated in another clinical trial, not pre-approved by Organon, within 30 days of entering into CT 19.4.312.